RWE Study in the Treatment of Cervical Lesions of Various Etiology

NCT ID: NCT05668806

Last Updated: 2022-12-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

345 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-05-20

Study Completion Date

2021-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study was to assess the post-market performance and tolerability of Cerviron® ovules in the treatment and management of cervical lesions of different etiologies. The study included clinical data related to aspect of lesions performed during routine colposcopy exams, the degree of re-epithelialization of the cervical mucosa, vaginal pH, pain level, and vaginal bleeding level.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is an observational, post-marketing study conducted between May-July 2021.

The aim of the study was to assess the post-market performance and tolerability of Cerviron® ovules in the treatment and management of cervical lesions of different etiologies.

The secondary objective of this clinical investigation is the assessment of performance of the medical device by clinical exam and patients' degree of satisfaction related to the use of the medical device.

The study population included 345 participants aged 20-70 years with either a cervical lesion under treatment or with recent surgical removal of a cervical lesion.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cervical Lesion Vaginal Bleeding

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

cervical ectropion vaginal discharge cervix lesion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cerviron

Cerviron® is an invasive medical device of short-term use classified under annex VIII of the European Regulation 2017/745 as class IIb according to Rule 21 (devices composed of substances or of combinations of substances to be introduced into the human body via a body orifice or applied to the skin and absorbed by or locally dispersed in the human body). Cerviron® has a complex composition consisting of three topical pharmaceutical products - hexylresorcinol, collagen and bismuth subgallate - and four phytotherapeutic extracts - Calendula officinalis, Hydrastis canadensis, Thymus vulgaris extract and Curcuma longa. The Instructions for use specify its field of use as adjuvant in the treatment of acute and chronic vulvovaginitis of mechanical etiology, caused by changes of vaginal pH and changes of the vaginal flora and of cervical lesions of mechanical origin.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with a clearly diagnosed non-infectious gynecological disease and patients with traumatic or surgical lesions.
* Patients with either of the following medical history: trauma of the cervix, pain, bleeding after sexual intercourse, postpartum injuries or postoperative cervical lesions.

Exclusion Criteria

* Patients with cervical cancer.
* Patients with vulvar cancer
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

MDX Research

NETWORK

Sponsor Role collaborator

Perfect Care Distribution

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ema Peta

Role: STUDY_DIRECTOR

Perfect Care Distribution

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Spitalul Clinic Dr. Ion Cantacuzino Bucharest

Bucharest, , Romania

Site Status

Med Life Humanitas Cluj-Napoca

Cluj-Napoca, , Romania

Site Status

Cabinet Medical - Dr. Saleh K. Majed

Craiova, , Romania

Site Status

Cabinet Medical - Dr. Surpanelu Oana

Iași, , Romania

Site Status

MediBlue

Iași, , Romania

Site Status

Clinica Natisan Pitesti

Piteşti, , Romania

Site Status

Cabinet Dr. Rădulescu G. Mihaela Elena

Râmnicu Vâlcea, , Romania

Site Status

Ramnicu Valcea

Râmnicu Vâlcea, , Romania

Site Status

Cabinet Ginecologic Dr. Popescu Sibiu

Sibiu, , Romania

Site Status

Clinica iMED

Sibiu, , Romania

Site Status

Pan Medical Sibiu

Sibiu, , Romania

Site Status

Bradmed SRL

Târgu Jiu, , Romania

Site Status

Cabinet Dr. Ioana Trotea Targu Jiu

Târgu Jiu, , Romania

Site Status

Clinica Medicala Dr. Cioata Ionel Trifon

Timișoara, , Romania

Site Status

Spitalul Judetean de Urgenta Tulcea

Tulcea, , Romania

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Romania

References

Explore related publications, articles, or registry entries linked to this study.

Petre I, Sirbu DT, Petrita R, Toma AD, Peta E, Dimcevici-Poesina F. Real-world study of Cerviron(R) vaginal ovules in the treatment of cervical lesions of various etiologies. Biomed Rep. 2023 Jul 7;19(2):54. doi: 10.3892/br.2023.1618. eCollection 2023 Aug.

Reference Type DERIVED
PMID: 37546352 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CYRONRW/02/2022

Identifier Type: -

Identifier Source: org_study_id